## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## **BOX PCT/DO-EO**

Commissioner for Patents Washington, D.C. 20231

"Express Mail" mailing label number EL 823 521 240 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and addressed to: Commissioner of Patents, Washington, DC 20231, on July 13, 2001.

Colleen Hanagan

## NATIONAL STAGE APPLICATION TRANSMITTAL LETTER **APPLICATION FILING UNDER 35 U.S.C. § 371**

Transmitted herewith for filing is the patent application of:

Inventor(s)/Applicant(s):

Ruelle, Jean-Louis and Thonnard, Joelle

**International Application No.:** 

PCT/EP00/00135

International Published Appln. No.: WO 00/42191

**International Filing Date:** 

10 January 2000 15 January 1999, 28 January 1999,

**Priority Filing Dates:** 

29 January 1999, 09 February 1999, 10 February 1999, 20 February 1999, 23 February 1999 & 25 February 1999

**Thirty Month Date:** 

15 July 2001

Title:

"NOVEL COMPOUNDS"

THIS NEW APPLICATION IS A NATIONAL STAGE APPLICATION UNDER PCT, CHAPTER II WITH A REQUEST FOR EXAMINATION WITHOUT DELAY TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US).

$\bowtie$	This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. §
	371;
	This is a SECOND or subsequent submission of items concerning a filing
	under 35 U.S.C. § 371.

This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).

3. month		er Demand for International Preliminary Examination was made by the 19 <sup>11</sup> e earliest claimed priority date.
4. 1.495(		ed items are required for filing under 37 CFR § 1.53(b) and § 1.494(b) or §
	$\boxtimes$	One copy of International Publication No. WO 00/42191
	(a)	is transmitted herewith (required only if not transmitted by the International Bureau)
	(b)	has been transmitted by the International Bureau
	(c)	is not required, as the application was filed in the United States Receiving Office (RO/US)
<u>Fees</u>		
	$\boxtimes$	The basic national fee set forth in 37 CFR § 1.482 - International Preliminary
	nation F <b>\$860.00</b>	ee not paid to USPTO but International Search Report prepared by the EPO or
	$\boxtimes$	Claims in Excess of 20 (2 @ \$18.00)
		Independent Claims in Excess of 3 ( @ \$80.00)
5.	Further	r enclosed are:
	$\boxtimes$	One copy of International Preliminary Examination Report.
	$\boxtimes$	One copy of International Search Report.
		One copy of Written Opinion.
		One copy of PCT Request as filed.
		One copy of Chapter II Demand as filed.
6. 371(c)	(2))	A translation of the International Application into English (35 U.S.C. §
7. 19 (35	U.S.C.	Amendments to the claims of the International Application under PCT Article § 371(c)(3))
8. § 371(	c)(3))	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C.
9.	Still ad	ditional papers enclosed:
		Assignment with Assignment Recordation Form Cover Sheet
		Verification Statement Claiming Small Entity Status
		Declaration or oath is enclosed executed by the inventor
		An Information Disclosure Statement under 37 CFR § 1.97 and § 1.98
	$\square$	Return Acknowledgment Postcard

10. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) Enclosed are: A. X Computer Readable Copy of the Sequence Listing (a) X Paper Copy (identical to Computer Readable Copy) of the (b) Sequence Listing B. Enclosed is a paper copy of the Sequence Listing. This paper copy and a Computer Readable Form thereof are identical with the Computer Readable Form in another application of the Applicant which is fully identified as follows: U.S. Application No.: @@ Filed: (a)(a) Attorney Docket No.: @@ which is believed to comply with the rules set forth in 37 CFR § 1.821 et. seq. Applicants requests pursuant to 37 CFR § 1.821(e) that this Computer Readable Form be used in the present application. Please TRANSFER the sequence listing from the parent to this application. X C. Statement under 37 CFR § 1.821(f): The information recorded in computer readable form is identical to the written Sequence Listing. D. Statement under 37 CFR § 1.821(g) (required when Sequence Listing not submitted at the time of filing under 35 U.S.C. §111(a)) or 37 CFR §1.821(f) (required when Sequence Listing not submitted at the time of filing under the Patent Cooperation Treaty): The submission of the Sequence Listing includes no new matter. X E. Amendment: Please enter the Sequence Listing into the application. **Preliminary Amendment** Prior to calculation of fees, kindly enter:  $\boxtimes$ Preliminary Amendment submitted herewith do not enter Preliminary Amendment

11.

12. The correspondence address for this application is the Customer No. provided below:

Insert Bar Code Label Here:

25308
PATENT\_TRADEMARK OFFICE

13. Fee payment being made at this time is enclosed:

\* Basic filing fee (\$860.00)

860.00

\* Claims in Excess of 20

36.00

\* (2 @ \$18.00)

Independent Claims in Excess of 3

00.00

\* Total Fees enclosed:

\$896.00

14. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 50-0258. This letter is filed in duplicate for accounting purposes.

Respectfully submitted,

Date: July 13, 2001

Eric A. Meade

Registration No. 42,876

for

Allen Bloom

Registration No. 29,135

Attorney for Applicant

DECHERT

Princeton Pike Corporate Center

PO Box 5218

Princeton, New Jersey 08543-5218

Allen Bloom (609) 620-3214

Eric A. Meade (609) 620-3248

Fax: (609) 620-3259

Attn.: Allen Bloom, Esq.

(609) 620-3214

114937.1,07